A detailed history of Invesco Ltd. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 85,539 shares of SAGE stock, worth $908,424. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,539
Previous 64,056 33.54%
Holding current value
$908,424
Previous $1.39 Million 15.49%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$18.62 - $26.95 $400,013 - $578,966
21,483 Added 33.54%
85,539 $1.6 Million
Q4 2023

Feb 12, 2024

SELL
$17.1 - $22.26 $37,431 - $48,727
-2,189 Reduced 3.3%
64,056 $1.39 Million
Q3 2023

Nov 13, 2023

SELL
$16.75 - $48.98 $732,963 - $2.14 Million
-43,759 Reduced 39.78%
66,245 $1.36 Million
Q2 2023

Aug 11, 2023

BUY
$40.65 - $59.54 $2.08 Million - $3.04 Million
51,104 Added 86.76%
110,004 $5.17 Million
Q1 2023

May 12, 2023

SELL
$37.27 - $46.57 $1.06 Million - $1.32 Million
-28,400 Reduced 32.53%
58,900 $2.47 Million
Q4 2022

Feb 13, 2023

BUY
$32.2 - $43.61 $64,142 - $86,871
1,992 Added 2.34%
87,300 $3.33 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $62,784 - $84,160
-1,945 Reduced 2.23%
85,308 $3.34 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $532,236 - $734,726
-19,340 Reduced 18.14%
87,253 $2.82 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $1.49 Million - $2.21 Million
48,408 Added 83.2%
106,593 $3.53 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $2.53 Million - $3.22 Million
-68,292 Reduced 54.0%
58,185 $2.48 Million
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $17.3 Million - $24.7 Million
-429,727 Reduced 77.26%
126,477 $5.6 Million
Q2 2021

Aug 17, 2021

SELL
$54.88 - $79.29 $51.1 Million - $73.9 Million
-931,613 Reduced 62.62%
556,204 $31.6 Million
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $227,775 - $311,954
3,224 Added 0.22%
1,487,817 $111 Million
Q4 2020

Feb 16, 2021

SELL
$58.41 - $89.06 $601,214 - $916,694
-10,293 Reduced 0.69%
1,484,593 $128 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $10 Million - $15.2 Million
-243,522 Reduced 14.01%
1,494,886 $91.4 Million
Q2 2020

Aug 14, 2020

SELL
$25.95 - $43.15 $628,067 - $1.04 Million
-24,203 Reduced 1.37%
1,738,408 $72.3 Million
Q1 2020

May 15, 2020

SELL
$26.15 - $77.24 $6.72 Million - $19.8 Million
-256,945 Reduced 12.72%
1,762,611 $50.6 Million
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $11.3 Million - $29.1 Million
187,763 Added 10.25%
2,019,556 $146 Million
Q3 2019

Nov 14, 2019

SELL
$140.29 - $189.96 $26.7 Million - $36.1 Million
-190,171 Reduced 9.41%
1,831,793 $257 Million
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $212 Million - $246 Million
1,341,720 Added 197.24%
2,021,964 $370 Million
Q1 2019

May 15, 2019

BUY
$89.33 - $163.65 $4.03 Million - $7.38 Million
45,095 Added 7.1%
680,244 $108 Million
Q4 2018

Feb 14, 2019

BUY
$81.94 - $139.71 $52 Million - $88.7 Million
635,149 New
635,149 $60.8 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $631M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.